News
J&J's multiple myeloma duo aces phase 3 trial
Two of Johnson & Johnson's multiple myeloma bispecifics, Tecvayli and Talvey, have dramatically improved survival when used as a second-line regimen.
News
EU clears AZ's SERD camizestrant, as FDA review drags on
AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.
News
Nuvalent buy delivers new cancer approval for GSK
GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.
Oncology
Sponsored
Establishing ctDNA as a validated primary surrogate endpoint
Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
News
Repligen builds in cell therapy with $1.5bn BioLife takeover
Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
